US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Silexion Therapeutics Corp

1.02

-0.0200-1.92%

Pre-market: 1.020.00000.00%04:53 EDT

Volume:17.31K

Turnover:17.93K

Market Cap:4.16M

PE:-0.11

High:1.10

Open:1.10

Low:1.02

Close:1.04

52wk High:22.36

52wk Low:0.9701

Shares:4.07M

Float Shares:4.04M

Volume Ratio:0.31

T/O Rate:0.43%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-8.9597

EPS(LYR):-395.3595

ROE:-771.23%

ROA:-144.27%

PB:1.60

PE(LYR):0.00

Loading ...

Overview Company News Filings

Silexion Therapeutics removes Ilan Levin from board; change effective immediately

Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204

Silexion Therapeutics Corp: Expects to Initiate Human Clinical Trials in Q2 of 2026

THOMSON REUTERS

Silexion Therapeutics: to Submit Phase 2/3 Clinical Trial Application in Germany by Qtr-End, Extra Regulatory Filings Across EU in Early 2027

THOMSON REUTERS

Silexion Therapeutics Receives Approval From Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer

THOMSON REUTERS

Israeli Health Ministry clears Silexion Phase 2/3 trial of SIL204 in pancreatic cancer

Silexion Therapeutics reconvened shareholder meeting with 36.6% of shares represented

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Silexion Therapeutics (SLXN)

Press Release: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Silexion Therapeutics FY 2025 net loss narrows 27.9% to USD 11.91 million

Silexion Therapeutics Corp. Announces Date for Extraordinary General Meeting

Silexion Therapeutics unveils siRNA approach targeting KRAS mutations in pancreatic and other cancers

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Silexion Therapeutics Publishes 2025 Shareholder Letter Highlighting Major Achievements

Silexion Therapeutics Reports Strong Preclinical Tumor Inhibition With SIL204 in KRAS-Mutated Cancers

Silexion Therapeutics Submits Phase 2/3 Clinical Trial Application for SIL204 in Israel

Silexion Therapeutics Initiated at Buy by Litchfield Hills

BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical

Silexion Therapeutics Corp - on Track to Initiate Phase 2/3 Trial in H1 2026

THOMSON REUTERS

Silexion Therapeutics Corp - Regulatory Submissions in Israel by Q4 2025, Germany by Q1 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SLXN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.02,"timestamp":1776283200000,"preClose":1.04,"halted":0,"volume":17307,"hourTrading":{"tag":"盘前","latestPrice":1.02,"preClose":1.02,"latestTime":"04:53 EDT","volume":2,"amount":2.04,"timestamp":1776329597218,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.019230769230769246,"floatShares":4040000,"shares":4074700,"eps":-8.959658,"marketStatus":"Pre-Mkt","change":-0.02,"latestTime":"04-16 07:23:00 EDT","open":1.1,"high":1.1,"low":1.02,"amount":17925.4898748,"amplitude":0.076923,"askPrice":1.19,"askSize":200,"bidPrice":0.6402,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-8.959658,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776346200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.02,"preHourTrading":{"tag":"盘前","latestPrice":1.02,"preClose":1.02,"latestTime":"04:53 EDT","volume":2,"amount":2.04,"timestamp":1776329597218,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.02,"latestTime":"18:14 EDT","volume":1057,"amount":1123.065,"timestamp":1776291297667,"change":0.06,"changeRate":0.058824,"amplitude":0.058824},"volumeRatio":0.30964743091041613},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":4040000,"roa":"-144.27%","roe":"-771.23%","lyrEps":-395.359461,"volumeRatio":0.30964743091041613,"shares":4074700,"dividePrice":0,"high":1.1,"amplitude":0.076923,"preClose":1.04,"low":1.02,"week52Low":0.9701,"pbRate":"1.60","week52High":22.36,"institutionHeld":0,"latestPrice":1.02,"committee":-0.333333,"eps":-8.959658,"divideRate":0,"volume":17307,"delay":0,"ttmEps":-8.959658,"open":1.1,"prevYearClose":1.92,"prevWeekClose":1.05,"prevMonthClose":1.28,"prevQuarterClose":1.28,"fiveDayClose":1.12,"twentyDayClose":1.56,"sixtyDayClose":2.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1765857600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2026-04-15","current":-0.113844,"percent":0.661157,"low":-1.070842,"twenty":-0.584956,"median":-0.41963,"eighty":-0.131586,"high":-0.075397,"avg":-0.412555,"sd":0.235458,"marketCap":3464016},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-05","current":-1.070842,"twenty":-0.471245,"median":-0.259284,"eighty":-0.119953,"marketCap":9902075},{"date":"2025-12-12","current":-1.0279,"twenty":-0.478706,"median":-0.282158,"eighty":-0.120362,"marketCap":9504991},{"date":"2025-12-19","current":-0.821644,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"marketCap":7597740},{"date":"2025-12-26","current":-0.797975,"twenty":-0.491377,"median":-0.316599,"eighty":-0.121181,"marketCap":7378875},{"date":"2026-01-02","current":-0.6492,"twenty":-0.495368,"median":-0.386196,"eighty":-0.12159,"marketCap":6003152},{"date":"2026-01-09","current":-0.710063,"twenty":-0.504027,"median":-0.401489,"eighty":-0.122205,"marketCap":6565948},{"date":"2026-01-16","current":-0.825025,"twenty":-0.510588,"median":-0.409651,"eighty":-0.122955,"marketCap":7629006},{"date":"2026-01-23","current":-0.726969,"twenty":-0.515839,"median":-0.412313,"eighty":-0.12316,"marketCap":6722280},{"date":"2026-01-30","current":-0.662725,"twenty":-0.574408,"median":-0.414769,"eighty":-0.123296,"marketCap":6128218},{"date":"2026-02-06","current":-0.510569,"twenty":-0.606596,"median":-0.415025,"eighty":-0.12391,"marketCap":4721229},{"date":"2026-02-13","current":-0.534237,"twenty":-0.597129,"median":-0.417327,"eighty":-0.124456,"marketCap":4940094},{"date":"2026-02-20","current":-0.534237,"twenty":-0.591719,"median":-0.41963,"eighty":-0.125548,"marketCap":4940094},{"date":"2026-02-27","current":-0.588338,"twenty":-0.588338,"median":-0.42265,"eighty":-0.127254,"marketCap":5440357},{"date":"2026-03-06","current":-0.557906,"twenty":-0.584956,"median":-0.42723,"eighty":-0.127936,"marketCap":5158959},{"date":"2026-03-13","current":-0.563418,"twenty":-0.591719,"median":-0.432424,"eighty":-0.128618,"marketCap":5209923},{"date":"2026-03-20","current":-0.377654,"twenty":-0.588338,"median":-0.436237,"eighty":-0.128618,"marketCap":4498612},{"date":"2026-03-27","current":-0.366297,"twenty":-0.584956,"median":-0.430786,"eighty":-0.128959,"marketCap":4363328},{"date":"2026-04-02","current":-0.341131,"twenty":-0.584956,"median":-0.423383,"eighty":-0.129233,"marketCap":4063557},{"date":"2026-04-10","current":-0.310374,"twenty":-0.584956,"median":-0.420859,"eighty":-0.131075,"marketCap":3697171},{"date":"2026-04-15","current":-0.290801,"twenty":-0.584956,"median":-0.41963,"eighty":-0.131586,"marketCap":3464016}],"updateTime":1776338575485},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622049150","title":"Silexion Therapeutics removes Ilan Levin from board; change effective immediately","url":"https://stock-news.laohu8.com/highlight/detail?id=2622049150","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622049150?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:07","pubTimestamp":1774469253,"startTime":"0","endTime":"0","summary":"The board approved the removal through a unanimous written determination by the other directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL6XVlWt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621098238","title":"Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204","url":"https://stock-news.laohu8.com/highlight/detail?id=2621098238","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621098238?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:50","pubTimestamp":1774360215,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced that it has received formal approval from the Israeli Ministry of Health to initiate its Phase 2/3 clinical ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-approved-to-initiate-phase-2-3-clinical-trial-of-sil204-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-approved-to-initiate-phase-2-3-clinical-trial-of-sil204-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","SLXN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621106216","title":"Silexion Therapeutics Corp: Expects to Initiate Human Clinical Trials in Q2 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621106216","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621106216?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:37","pubTimestamp":1774355843,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0N8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062198","title":"Silexion Therapeutics: to Submit Phase 2/3 Clinical Trial Application in Germany by Qtr-End, Extra Regulatory Filings Across EU in Early 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062198?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:37","pubTimestamp":1774355843,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0N8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062166","title":"Silexion Therapeutics Receives Approval From Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062166?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:37","pubTimestamp":1774355843,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062113","title":"Israeli Health Ministry clears Silexion Phase 2/3 trial of SIL204 in pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062113","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062113?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:37","pubTimestamp":1774355833,"startTime":"0","endTime":"0","summary":"Israel’s Ministry of Health approved Silexion to initiate a Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer.The company said it expects to start human clinical trials in Q2 2026.Silexion plans to submit a Phase 2/3 clinical trial application in Germany by the end of the current quarter.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL4wG8rV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","BK4112","IE00BN0W2V16.EUR","SLXN","IE00BN0W2T93.GBP","SG9999014021.USD","BK4585","BK4588","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014039.USD","BK4139","IE00BKPKM429.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621844540","title":"Silexion Therapeutics reconvened shareholder meeting with 36.6% of shares represented","url":"https://stock-news.laohu8.com/highlight/detail?id=2621844540","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621844540?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:32","pubTimestamp":1774297973,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics held a reconvened extraordinary general meeting on March 23, 2026.Shareholders did not approve an increase in authorized share capital by 50,000,000 ordinary shares, from 9,000,000 to 59,000,000.An amendment to the 2024 equity incentive plan’s evergreen provision, effective January 1, 2026, was not approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2JGk1f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620221708","title":"Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Silexion Therapeutics (SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620221708","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620221708?lang=en_us&edition=fundamental","pubTime":"2026-03-19 22:50","pubTimestamp":1773931805,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gossamer Bio (GOSS) and Silexion Therapeutics (SLXN)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gossamer-bio-goss-and-silexion-therapeutics-slxn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gossamer-bio-goss-and-silexion-therapeutics-slxn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN","LU0029874061.USD","LU0128526141.USD","BK4588","BK4585","BK4137","BK4581","XBI","GOSS","BK4139","LABU","XLV","HCSG","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620861405","title":"Press Release: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620861405","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620861405?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:01","pubTimestamp":1773781260,"startTime":"0","endTime":"0","summary":"Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer, reinforcing broad therapeutic potential. During the fourth quarter, Silexion achieved key clinical readiness milestones including completing two-species toxicology studies, written Scientific Advice from Germany's BfArM, and submission of Phase 2/3 clinical trial application to the Ministry of Health in Israel for SIL204 in locally advanced pancreatic cancer. The Company remains on track to initiate Phase 2/3 clinical trial in the first half of 2026, with Israel regulatory feedback anticipated by the end of Q1 2026. Regulatory Advancement Toward Phase 2/3 Initiation: Silexion received written Scientific Advice from Germany's Federal Institute for Drugs and Medical Devices  regarding the design of its planned Phase 2/3 clinical trial. The Company subsequently submitted its Phase 2/3 clini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4503","BK4551","API","SLXN","BK4023","LENZ","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620403289","title":"Silexion Therapeutics FY 2025 net loss narrows 27.9% to USD 11.91 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620403289","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620403289?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:49","pubTimestamp":1773780563,"startTime":"0","endTime":"0","summary":"Silexion published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 11.91 million. Research and development expense rose 22.4% to USD 7.14 million, mainly due to higher subcontractor and consultant costs tied to GMP API batches and formulation work ahead of a planned human clinical trial expected in Q2 2026, contingent on regulatory clearance. General and administrative expense fell 33.8% to USD 4.49 million, driven mainly by lower non-cash share-based compensation, partly offset by higher professional services costs related to operating as a public company. Net cash used in operating activities increased 28.6% to USD 10.82 million, while cash and cash equivalents totaled USD 6.0 million as of Dec. 31, 2025. Management said current cash is expected to fund operations for only several months from the filing date and that additional capital will be needed.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL4g7dTR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611853193","title":"Silexion Therapeutics Corp. Announces Date for Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2611853193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611853193?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:10","pubTimestamp":1771017037,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has announced that it will hold an extraordinary general meeting in March 2026 at the offices of Meitar Law Offices in Ramat Gan, Israel. During the meeting, shareholders will vote on the Authorized Share Capital Increase Proposal and the Evergreen Increase Proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL4K2Bns:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608877601","title":"Silexion Therapeutics unveils siRNA approach targeting KRAS mutations in pancreatic and other cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2608877601","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608877601?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:33","pubTimestamp":1770129232,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has provided an update on its lead product, SIL204, a first-in-class, isoform-selective pan-KRAS silencer designed for targeted cancer therapy. The presentation highlights the use of siRNA technology to silence mutated KRAS, the most common oncogenic driver in several human cancers, including pancreatic, colorectal, and non-squamous non-small cell lung cancer. SIL204 is engineered for dual administration—systemic and intratumoral—to address both primary tumors and metastatic disease, particularly in pancreatic ductal adenocarcinoma . The company reports that SIL204 binds extensively to low-density lipoproteins , exploiting the increased LDL receptor expression in pancreatic cancer cells to enhance targeted delivery. Preclinical and Phase 2 clinical data from earlier siRNA candidates, as well as the development plan for SIL204, are included in the presentation. You can access the full presentation through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL6S6KT5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605107703","title":"Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2605107703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605107703?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:30","pubTimestamp":1769002230,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp., a clinical-stage biotechnology company focused on oncology, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29, 2026, in Boston, MA. Company management, including CEO Ilan Hadar, will participate in the event, and Silexion will also be an official partner of the summit. Silexion is developing SIL204, a next-generation siRNA therapy targeting mutated KRAS oncogenes, with plans to initiate a Phase 2/3 clinical study in locally advanced pancreatic cancer in mid-2026. Interested parties can arrange one-on-one meetings with Silexion management through the company’s investor relations representatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL7ykQd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014013.SGD","NDAQ","LU2210150020.SGD","BK4585","BK4588","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014021.USD","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","SLXN","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601890363","title":"Silexion Therapeutics Publishes 2025 Shareholder Letter Highlighting Major Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890363","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890363?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:25","pubTimestamp":1767705917,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has published a shareholder letter from Chairman and Chief Executive Officer Ilan Hadar. The letter highlights achievements in 2025, including positive preclinical data for SIL204, completion of regulatory toxicology studies, and positive feedback from Germany’s Federal Institute for Drugs and Medical Devices regarding Phase 2/3 trial design. The letter also outlines plans to initiate a Phase 2/3 clinical trial in locally advanced pancreatic cancer in the first half of 2026 and discusses expected milestones for the upcoming year. The full letter can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL5TLjpW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601560892","title":"Silexion Therapeutics Reports Strong Preclinical Tumor Inhibition With SIL204 in KRAS-Mutated Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2601560892","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601560892?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:30","pubTimestamp":1767702609,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has announced significant preclinical research results for its lead RNA interference  therapy, SIL204, targeting KRAS-driven cancers. The company reported that SIL204 demonstrated substantial tumor inhibition in human KRAS-mutated cancer cell line models, including pancreatic, colorectal, and lung cancers. These findings, achieved in 2025, have not yet been presented in human clinical trials, which are scheduled to begin in the first half of 2026. Silexion also completed regulatory toxicology studies and received positive feedback from Germany's Federal Institute for Drugs and Medical Devices  on its Phase 2/3 trial design, paving the way for the upcoming clinical trial of SIL204 in locally advanced pancreatic cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL3cF3Gk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","SLXN","NDAQ","BK4588","SG9999014005.SGD","LU0314104364.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","BK4139","SG9999014013.SGD","BK4112","BK4585","IE00B64PRP62.GBP","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591998763","title":"Silexion Therapeutics Submits Phase 2/3 Clinical Trial Application for SIL204 in Israel","url":"https://stock-news.laohu8.com/highlight/detail?id=2591998763","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591998763?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:40","pubTimestamp":1765892410,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp. has announced the submission of its regulatory application in Israel to initiate a Phase 2/3 clinical trial of SIL204 for patients with locally advanced pancreatic cancer. This regulatory submission follows positive feedback from the German Federal Institute for Drugs and Medical Devices  and successful toxicology studies demonstrating no systemic organ toxicity. Silexion plans to file additional regulatory applications in Germany and the European Union in the first quarter of 2026, with expansion to U.S. clinical sites anticipated after the safety run-in is completed in Israel and Germany. The Israeli portion of the trial will be conducted in collaboration with Sheba Medical Center, pending regulatory and ethics approvals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL6vPlbm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","BK4585","SG9999014013.SGD","BK4139","IE00BGHQF748.EUR","SG9999014039.USD","SG9999014021.USD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210150020.SGD","LU2210149790.SGD","NDAQ","SLXN","BK4112","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591665647","title":"Silexion Therapeutics Initiated at Buy by Litchfield Hills","url":"https://stock-news.laohu8.com/highlight/detail?id=2591665647","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591665647?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:55","pubTimestamp":1765810500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLXN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 09:55 ET (14:55 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","LENZ","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588056944","title":"BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056944","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056944?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:55","pubTimestamp":1764683748,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical Dec 2 (Reuters) - Silexion Therapeutics Corp SLXN.O:SILEXION THERAPEUTICS RECEIVES P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4MJNPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588053763","title":"Silexion Therapeutics Corp - on Track to Initiate Phase 2/3 Trial in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053763?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4MJNPK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588053083","title":"Silexion Therapeutics Corp - Regulatory Submissions in Israel by Q4 2025, Germany by Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053083?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4MJNPK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}